Replies to post #86066 on Biotech Values

[tony111]

Bad deal for BMS. The IL-6 antagonist approved in Japan increases overall death rate if I recall correctly.

[mcbio]

Re: BMY/Alder RA deal

I find this news particularly bearish for RIGL inasmuch as BMY passed on RIGL's R788, an oral RA compound, in favor of this injectable drug from Alder. I'm sure big pharma is well aware of the potential concerns for R788 as outlined in the article previously posted by Peter. See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42840803&txt2find=rigl